3 recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 3 |
| Phase 1 | 1 | Recruiting 1 |
Follow Rina-S: new trials by email Literature Review of Rina-S trials Research Report on Rina-S
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers Rina-S - Gastrointestinal Cancers | Phase 2 | Recruiting | Genmab | 160 | 2026-05-11 | 2026-11-03 |
| Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer Rina-S - Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Recruiting | Genmab | 240 | 2026-01-30 | 2026-11-03 |
| Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) Rina-S, Carboplatin, Bevacizumab - High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer | Phase 1 / Phase 2 | Recruiting | Genmab | 952 | 2022-12-07 | 2026-11-04 |
Carcinoma, Non-Small-Cell Lung (2) · Breast Neoplasms (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Gastrointestinal Neoplasms (1) · Mesothelioma (1) · Ovarian Neoplasms (1) · Triple Negative Breast Neoplasms (1) · Uterine Cervical Neoplasms (1) · Uterine Neoplasms (1)
Genmab (3)
Japan (3) · South Korea (3) · United States (3) · Australia (2) · Belgium (2) · China (2) · France (2) · Germany (2) · Netherlands (2) · Spain (2) · Taiwan (2) · Hungary (1) · Italy (1) · Poland (1) · United Kingdom (1)
2025 (2)